Skip to content


  • Meeting abstract
  • Open Access

PW02-018 - Impact of PSTPIP1 mutaions on clinical phenotype

  • 1, 2,
  • 3,
  • 1,
  • 1,
  • 1,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11,
  • 12,
  • 13,
  • 13,
  • 13,
  • 14,
  • 15,
  • 16,
  • 17,
  • 2,
  • 18,
  • 18,
  • 18,
  • 18 and
  • 1
Pediatric Rheumatology201311 (Suppl 1) :A158

  • Published:


  • Glutamic Acid
  • Clinical Phenotype
  • Cytokine Profile
  • Heterozygous Carrier
  • E275K Mutation


Hyperzincaemia and hypercalprotectinaemia (Hz/Hc), a rare condition within the spectrum of autoinflammatory diseases, is associated with hepatosplenomegaly, arthritis, anemia, cutaneous inflammation, and failure to thrive. So far, no genetic cause has been identified. While the clinical appearance is heterogeneous, all affected individuals present with extremely elevated MRP8/MRP14 (calprotectin) serum concentrations (0.9-12.0 g/l (normal range < 0.001 g/l)).


The clinical phenotype of 12 patients was characterized and compared to 11 patients with classical PAPA syndrome. Screening of candidate genes was performed to identify disease-causing mutations.


Serum concentrations of MRP8/14 complex were analyzed in 12 patients with Hz/Hc and compared to 11 PAPA patients. Candidate exons of these patients were sequenced. Cytokine profile of 12 patients with PSTPIP1 mutations was analyzed by mulitplex ELISA. MRP8/14 secretion from patient´s PBMCs was measured and activity of patient`s sera on monocytes evaluated. The clinical phenotype of all enrolled patients was characterized and compared.


Ten of twelve patients were heterozygous carriers of a glutamic acid 250 (GAG)→lysine (AAG)/p.Glu250Lys/E250K substitution and 1 patient of a glutamic acid 257 (GAG)→lysine (AAG)/p.Glu250Lys/E257K substitution in exon 11 of the PSTPIP1 gene. MRP8/MRP14 concentrations were extremely elevated in these patients (0.9-12 g/l) compared to eleven patients presenting with classical PAPA symptoms (0.02-0.35 g/l), whose levels again were significantly higher compared to normal controls. Cytokine profiling confirmed the heterogeneity of PSTPIP1 mutations with a distinct profile for the Hz/Hc phenotype. MRP8/14 hypersecretion was found in PBMCs of patients with PSTPIP1 mutations and the serum of patients with active disease showed co-stimulatory properties on monocytes activated with TLR-1 ligands.


The novel PSTPIP1 E250K and E275K mutations cause an autoinflammatory disorder known as hyperzincaemia and hypercalprotectinaemia. The disease causes a heterogeneous spectrum of symptoms that only partially overlaps with the presentation of the classical PAPA syndrome. Elevated MRP8/14 levels are a common hallmark and biomarker of disorders caused by mutations in the PSTPIP1 gene.

Disclosure of interest

None declared.

Authors’ Affiliations

Institute of Immunology, University Hospital Muenster, Germany
Department of Paediatric Rheumatology and Immunology, University Children´s Hospital Muenster, Muenster, Germany
Department of Clinical Chemistry Großhadern, University Munich, Munich, Germany
Department of Pediatric Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, USA
2nd Division of Pediatrics, "G. Gaslini" Scientific Institute, Genova, Italy
Department of Immunology, Dr. Negrín University Hospital, Las Palmas de Gran Canaria, Spain
Immunology Department-CDB/IDIBAPS, Hospital Clinic, Barcelona, Spain
3rd Department of Pediatrics, Athens University Medical Faculty, Athens, Greece
Service de Génétique Médicale, Centre Hospitalo-Universitaire, Nantes, France
Department of Pediatrics and Neonatology, Nagoya City University, Nagoya, Japan
Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité University Hospital Berlin, Berlin, Germany
Department of Pediatrics, Stanford University Medical Center, Stanford, LA, USA
Division of Clinical Immunology and Allergy, Children's Hospital Los Angeles, LA, USA
Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Patenkirchen, Germany
Department of Clinical Chemistry, Charing Cross Hospital, London, UK
Department of Dermatology, University Hospital Muenster, Muenster, Germany
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Health, Bethesda, USA


© Holzinger et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.